Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2001 Dec;77(914):769–773. doi: 10.1136/pmj.77.914.769

Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions

P Mwaba 1, J Mwansa 1, C Chintu 1, J Pobee 1, M Scarborough 1, S Portsmouth 1, A Zumla 1
PMCID: PMC1742198  PMID: 11723315

Abstract

SETTING—Inpatient medical wards, Department of Medicine, University Teaching Hospital, Lusaka, Zambia.
OBJECTIVE—To define the natural history, clinical presentation, and management outcome of microbiologically confirmed cryptococcal meningitis in adult AIDS patients treated under local conditions where antifungal and antiretroviral therapies are not routinely available.
DESIGN—A descriptive, longitudinal, observational study.
METHODS—All adult patients admitted to the medical wards of the University Teaching Hospital, Lusaka, Zambia with cerebrospinal fluid culture proved, primary cryptococcal meningitis, during a 12 month period were enrolled into the study. The following details were acquired: clinical features, HIV status, laboratory data, treatment accorded, and survival.
RESULTS—A total of 230 patients with primary cryptococcal meningitis were studied (median age 32 years; range 15-65 years; 112 males, 118 females). Cryptococcal meningitis was the first AIDS defining illness in 210 (91%) patients. One hundred and thirty of the 230 (56%) patients had received treatment with fluconazole monotherapy and 100 (43%) patients received palliative care only without any antifungal therapy. A 100% case fatality rate was observed in both groups at follow up: by seven weeks in the untreated group and at six months in the fluconazole treated group. The cumulative median survival from time of diagnosis was 19 days (range 1-164 days) for the fluconazole treated group and 10 days (range 0-42 days) for the untreated group.
CONCLUSION—Cryptococcal meningitis, under current treatment accorded at the University Teaching Hospital, Lusaka, has a 100% mortality in young Zambian adults with AIDS. The current treatment accorded to Zambian adults with cryptococcal meningitis is inappropriate. An urgent need exists to improve strategies for the clinical management of AIDS patients in poor African countries. The wider ethical and operational issues of making available antifungals to African AIDS patients are discussed.


Keywords: cryptococcal meningitis; Africa; AIDS/HIV; natural history

Full Text

The Full Text of this article is available as a PDF (108.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aberg J. A., Powderly W. G. Cryptococcal disease: implications of recent clinical trials on treatment and management. AIDS Clin Rev. 1997:229–248. [PubMed] [Google Scholar]
  2. Antony S. J., Patel A., Leonard J. Use of fluconazole in the treatment of non-AIDS cryptococcal meningitis. J Natl Med Assoc. 1997 Oct;89(10):694–695. [PMC free article] [PubMed] [Google Scholar]
  3. Fylkesnes K., Musonda R. M., Kasumba K., Ndhlovu Z., Mluanda F., Kaetano L., Chipaila C. C. The HIV epidemic in Zambia: socio-demographic prevalence patterns and indications of trends among childbearing women. AIDS. 1997 Mar;11(3):339–345. doi: 10.1097/00002030-199703110-00012. [DOI] [PubMed] [Google Scholar]
  4. Haubrich R. H., Haghighat D., Bozzette S. A., Tilles J., McCutchan J. A. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. J Infect Dis. 1994 Jul;170(1):238–242. doi: 10.1093/infdis/170.1.238. [DOI] [PubMed] [Google Scholar]
  5. Heyderman R. S., Gangaidzo I. T., Hakim J. G., Mielke J., Taziwa A., Musvaire P., Robertson V. J., Mason P. R. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis. 1998 Feb;26(2):284–289. doi: 10.1086/516298. [DOI] [PubMed] [Google Scholar]
  6. Khanna N., Chandramuki A., Desai A., Ravi V. Cryptococcal infections of the central nervous system: an analysis of predisposing factors, laboratory findings and outcome in patients from South India with special reference to HIV infection. J Med Microbiol. 1996 Nov;45(5):376–379. doi: 10.1099/00222615-45-5-376. [DOI] [PubMed] [Google Scholar]
  7. Leenders A. C., Reiss P., Portegies P., Clezy K., Hop W. C., Hoy J., Borleffs J. C., Allworth T., Kauffmann R. H., Jones P. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997 Oct;11(12):1463–1471. doi: 10.1097/00002030-199712000-00010. [DOI] [PubMed] [Google Scholar]
  8. Maher D., Mwandumba H. Cryptococcal meningitis in Lilongwe and Blantyre, Malawi. J Infect. 1994 Jan;28(1):59–64. doi: 10.1016/s0163-4453(94)94161-0. [DOI] [PubMed] [Google Scholar]
  9. Mayanja-Kizza H., Oishi K., Mitarai S., Yamashita H., Nalongo K., Watanabe K., Izumi T., Ococi-Jungala, Augustine K., Mugerwa R. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis. 1998 Jun;26(6):1362–1366. doi: 10.1086/516372. [DOI] [PubMed] [Google Scholar]
  10. Menichetti F., Fiorio M., Tosti A., Gatti G., Bruna Pasticci M., Miletich F., Marroni M., Bassetti D., Pauluzzi S. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996 May;22(5):838–840. doi: 10.1093/clinids/22.5.838. [DOI] [PubMed] [Google Scholar]
  11. Moosa M. Y., Coovadia Y. M. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis. 1997 Feb;24(2):131–134. doi: 10.1093/clinids/24.2.131. [DOI] [PubMed] [Google Scholar]
  12. Powderly W. G. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996 May;22 (Suppl 2):S119–S123. doi: 10.1093/clinids/22.supplement_2.s119. [DOI] [PubMed] [Google Scholar]
  13. Sharkey P. K., Graybill J. R., Johnson E. S., Hausrath S. G., Pollard R. B., Kolokathis A., Mildvan D., Fan-Havard P., Eng R. H., Patterson T. F. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996 Feb;22(2):315–321. [PubMed] [Google Scholar]
  14. de Lalla F., Pellizzer G., Vaglia A., Manfrin V., Franzetti M., Fabris P., Stecca C. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis. 1995 Feb;20(2):263–266. doi: 10.1093/clinids/20.2.263. [DOI] [PubMed] [Google Scholar]
  15. van der Horst C. M., Saag M. S., Cloud G. A., Hamill R. J., Graybill J. R., Sobel J. D., Johnson P. C., Tuazon C. U., Kerkering T., Moskovitz B. L. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997 Jul 3;337(1):15–21. doi: 10.1056/NEJM199707033370103. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES